Our neuromuscular research program is focused on bridging the gap between clinical care and immunology, genetics and biochemistry. Our main research focus includes biomarker discovery and understanding immune-mediated neuromuscular diseases, such as myasthenia gravis (MG), and inflammatory neuropathies and myopathies (Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), Inclusion Body Myositis). We believe that close collaboration between clinicians and basic scientists is critical to successfully advancing our understanding of these disorders and translating these discoveries to patient care.
Our program is also a part of the Muscle Study Group (MSG), which is a consortium of scientific investigators among academic and research centers committed to collaborating on clinical and other research for muscle and neuromuscular diseases. We have initiated numerous studies, with a particular focus on MG, for which we conducted the first NIH-sponsored clinical trial. We are building upon early observations made by our group and others showing the benefit of B cell targeted therapy (rituximab) for MG by conducting further studies utilizing this approach. For more information, please visit this site.
We also belong to the Northeast ALS Consortium (NEALS), an international organization dedicated to ALS research. Multiple trials are currently available through this organization and we can assist patients who are interested in enrolling. For additional information please click here to visit the NEALS website. There are also many other active clinical trials across the United States and internationally. To view a list of all of these available trials please click here to visit the National Institute of Health online registry.
Visit yalestudies.org to view available clinical trials or learn more about clinical research at Yale.